ArticleThe Journal of infectious diseases2017
Stratification of Latent Mycobacterium tuberculosis Infection by Cellular Immune Profiling.
Article in The Journal of infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 45 citations in OpenAlex.
- Redefining Therapies for Drug-Resistant Tuberculosis: Synergistic Effects of Antimicrobial Peptides, Nanotechnology, and Computational Design.Advanced healthcare materials · 2026Review
- Identification of discriminative plasma protein biomarkers for recent Mycobacterium tuberculosis infection: a pilot data‑independent acquisition mass spectrometry‑based proteomics study.BMC infectious diseases · 2026Article
- Multiparameter antigen-specific immunoprofiling in subjects with negative IGRA and TST results with potentialFrontiers in cellular and infection microbiology · 2026Article
- Antigen-specific chemokine CCL3 as a biomarker for distinguishing between recent and remote tuberculosis infection.Infection · 2025Article
- A Blood and Biochemical Indicator-Based Prognostic Model Predicting Latent Tuberculosis Infection: A Retrospective Study.Tropical medicine and infectious disease · 2025Article
- High Mycobacterium bovis Exposure but Low IGRA Positivity in UK Farm Workers.Zoonoses and public health · 2025Article
- Advancement in diagnostic approaches for latent tuberculosis: distinguishing recent from remote infections.One health outlook · 2025Review
- Changes of Mycobacterium tuberculosis specific antigen-stimulated CD27European journal of medical research · 2024Article
- Diagnostic accuracy ofFrontiers in immunology · 2024Article
- Host Blood Transcriptional Signatures as Candidate Biomarkers for Predicting Progression to Active Tuberculosis.Tuberculosis and respiratory diseases · 2023Article
- Assessment of tuberculosis disease activity in people infected withEClinicalMedicine · 2022Article
- Defining the Role of Cellular Immune Signatures in Diagnostic Evaluation of Suspected Tuberculosis.The Journal of infectious diseases · 2022Article
- Study of CD27, CD38, HLA-DR and Ki-67 immune profiles for the characterization of active tuberculosis, latent infection and end of treatment.Frontiers in microbiology · 2022Article
- Know your tuberculosis epidemic-Is it time to add Mycobacterium tuberculosis immunoreactivity back into global surveillance?PLOS global public health · 2022Review
- CD38 Expression by Antigen-Specific CD4 T Cells Is Significantly Restored 5 Months After Treatment Initiation Independently of Sputum Bacterial Load at the Time of Tuberculosis Diagnosis.Frontiers in medicine · 2022Article
- Case-control diagnostic accuracy study of a non-sputum CD38-based TAM-TB test from a single milliliter of blood.Scientific reports · 2021Article
- Antigen-Specific T-Cell Activation Distinguishes between Recent and Remote Tuberculosis Infection.American journal of respiratory and critical care medicine · 2021Observational
- Immune profiling of Mycobacterium tuberculosis-specific T cells in recent and remote infection.EBioMedicine · 2021Article
- Lymphocyte-Related Immunological Indicators for StratifyingFrontiers in immunology · 2021Article
- Blood RNA signatures predict recent tuberculosis exposure in mice, macaques and humans.Scientific reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recently acquired and remotely acquired latent Mycobacterium tuberculosis infection (LTBI) are clinically indistinguishable, yet recent acquisition of infection is the greatest risk factor for progression to tuberculosis in immunocompetent individuals. We aimed to evaluate the ability of cellular immune signatures that differ between active tuberculosis and LTBI to distinguish recently from remotely acquired LTBI. Methods: Fifty-nine individuals were recruited: 20 had active tuberculosis, 19 had recently acquired LTBI, and 20 had remotely acquired LTBI. The proportion of mycobacteria-specific CD4+ T cells secreting tumor necrosis factor α (TNF-α) but not interferon γ or interleukin 2 which had a differentiated effector phenotype (TNF-α-only TEFF), and the level of CD27 expression on IFN-γ-producing CD4+ T cells, were detected by flow cytometry. Results: The TNF-α-only TEFF signature was significantly higher in the group with recently acquired LTBI, compared with the group with remotely acquired LTBI (P < .0001), and it discriminated between these groups with high sensitivity and specificity, with an area under the curve of 0.87. Two signatures incorporating CD27 expression did not distinguish between recently and remotely acquired LTBI. Interestingly, the TNF-α-only TEFF signature in participants with recently acquired LTBI was more similar to that in participants with tuberculosis than that in participants with remotely acquired LTBI, suggesting that recently acquired LTBI is immunologically more similar to tuberculosis than remotely acquired LTBI. Conclusions: These findings reveal marked biological heterogeneity underlying the clinically homogeneous phenotype of LTBI, providing a rationale for immunological risk stratification to improve targeting of LTBI treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.